Optimizing Neurology Prior Authorization with Cognizant TriZetto

For neurology practices leveraging Cognizant TriZetto as a critical component of their revenue cycle, streamlining prior authorization workflows is essential. Klivira's platform is engineered to optimize the complex interplay between neurology prior authorization requirements and the operational demands of Cognizant TriZetto.

Revenue cycle directors and prior authorization coordinators in neurology face unique challenges, including high volumes of complex specialty drug requests and stringent documentation requirements. Integrating a dedicated prior authorization automation platform with your existing Cognizant TriZetto infrastructure can significantly reduce manual overhead, accelerate approvals, and enhance financial performance. This synergy ensures that critical neurological treatments are authorized efficiently.

The Intersection of Neurology PA and Cognizant TriZetto Workflows

Neurology prior authorizations are dominated by high-cost, high-complexity treatments, including MS disease-modifying therapies, CGRP migraine biologics, and advanced imaging. Cognizant TriZetto, functioning as both a clearinghouse and a payer platform, is a common conduit for these authorization requests. Klivira bridges the gap between clinical documentation and the specific data requirements for submission through systems like TriZetto, ensuring that all necessary clinical context is accurately transmitted for review.

Key Neurology PA Triggers Processed via TriZetto

MS disease-modifying therapies (e.g., ocrelizumab, natalizumab, oral DMTs)
Alzheimer's disease therapeutics (e.g., lecanemab, donanemab) requiring amyloid confirmation
Migraine prevention biologics (CGRP monoclonal antibodies) and oral gepants
Spinal muscular atrophy / ALS treatments (e.g., nusinersen, onasemnogene abeparvovec)
Botox for chronic migraine, spasticity, and dystonia
Advanced imaging (e.g., brain MRI, amyloid PET for Alzheimer's diagnostics)

Navigating Documentation Requirements for Neurology Submissions

Neurology prior authorizations demand precise and comprehensive documentation, often guided by AAN Practice Guidelines. For MS DMTs, this includes McDonald criteria, EDSS scores, and relapse history. Alzheimer's anti-amyloid antibodies necessitate amyloid confirmation and MRI for ARIA screening. Klivira streamlines the extraction and structuring of this detailed clinical data from your EMR, preparing it for submission via X12 278 or ePA channels, common touchpoints for Cognizant TriZetto's clearinghouse services, minimizing manual data entry and potential errors.

Common Denial Reasons and Mitigation Strategies

Step therapy non-compliance for MS DMTs (e.g., requiring moderate-efficacy agents first)
Gaps in amyloid biomarker confirmation for Alzheimer's anti-amyloid antibodies
Failure to document prior oral preventive trials for CGRP migraine biologics
Insufficient evidence to meet chronic migraine criteria for Botox approval
Non-adherence to NCD/LCD-specific criteria for neuromodulation procedures like DBS

Klivira's Targeted Approach for Neurology PA Automation

Klivira's platform integrates with your EMR to automate data collection, apply AAN-guideline-aware step-therapy logic for MS, and track diagnostic biomarker documentation for Alzheimer's anti-amyloid therapies. This systematic approach ensures that submissions to payers, often processed through clearinghouses like Cognizant TriZetto, are complete and compliant. Our system manages chronic-treatment re-authorization workflows, reducing the administrative burden associated with ongoing neurological care.

EMR and Payer Touchpoints with Cognizant TriZetto Integration

Klivira facilitates seamless data exchange from your EMR, leveraging SMART on FHIR where available, to populate prior authorization requests. These structured requests are then submitted to payers through various channels, including X12 278 transactions or direct ePA portals, many of which are managed or facilitated by Cognizant TriZetto. This integration optimizes the flow of clinical and administrative data, ensuring that payer-specific rules and documentation requirements are met, whether for advanced imaging orders or high-cost specialty drug prescriptions.

Frequently asked questions

How does Klivira handle specific neurology drug PAs with TriZetto?

Klivira is configured to recognize the specific documentation requirements for high-volume neurology drugs like MS DMTs and CGRP biologics. We automate the extraction of necessary clinical data from your EMR and format it for submission via channels compatible with Cognizant TriZetto's clearinghouse services, ensuring all AAN guideline-based criteria are met.

Can Klivira help with re-authorizations for chronic neurology treatments?

Yes, Klivira's platform includes robust features for managing periodic re-authorizations, which are common for chronic neurology drugs. Our system tracks re-authorization dates and proactively initiates the workflow, ensuring continuity of care and preventing lapses in coverage for ongoing treatments.

Does Klivira integrate directly with Cognizant TriZetto's payer platform?

Klivira integrates with your EMR to streamline the creation of prior authorization requests. These requests are then submitted to payers through standard channels like X12 278 or ePA portals, which are often facilitated by clearinghouses and payer platforms such as Cognizetto TriZetto. This ensures efficient data transfer and processing within the existing healthcare infrastructure.

How does Klivira address complex documentation for Alzheimer's anti-amyloid therapies?

For Alzheimer's anti-amyloid antibodies, Klivira automates the collection of critical data points such as amyloid confirmation (PET or CSF), MRI for ARIA screening, and APOE genotype results from your EMR. This ensures that all required clinical evidence is included in the prior authorization submission, aligning with payer policies and AAN guidelines.

What is the benefit of using Klivira with Cognizant TriZetto for neurology imaging PAs?

Klivira streamlines prior authorizations for advanced neurology imaging like brain MRIs and amyloid PET scans. By automating the data submission process and ensuring compliance with payer-specific medical necessity criteria, we help accelerate approvals and reduce administrative burden, complementing the clearinghouse functions of Cognizant TriZetto for claim processing.